Tasmeer Hassan
Family Medicine · Carbondale, ILNPI 1801201538
Payments from drug & device makers
Across 172 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$441
- Lilly USA, LLC$408
- AstraZeneca$338
- Dexcom, Inc.$287
- Novo Nordisk$263
- Pfizer$193
- plus $925 from 20 others
What the payments were for
- Food & beverage$2,855100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $441 |
| Lilly USA, LLC | 24 | $408 |
| AstraZeneca | 24 | $338 |
| Dexcom, Inc. | 16 | $287 |
| Novo Nordisk | 17 | $263 |
| Pfizer | 12 | $193 |
| Braeburn Inc. | 8 | $184 |
| Boehringer Ingelheim | 8 | $101 |
| GSK | 5 | $87 |
| Merck | 4 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Indivior Inc. | 3 | $59 |
| Bayer | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Exact Sciences | 2 | $35 |
| Amgen | 2 | $33 |
| Viiv Healthcare Company | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$2,855 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $66,099 |
| JardianceEmpagliflozin | 32 | $38,521 |
| EliquisApixaban | 19 | $18,992 |
| TrulicityDulaglutide | 19 | $17,236 |
| MounjaroTirzepatide | 15 | $15,257 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,407 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,580 |
| Atorvastatin Calcium | 155 | $1,307 |
| Pravastatin Sodium | 26 | $815 |
| Omeprazole | 53 | $802 |
| Pregabalin | 36 | $760 |
| Famotidine | 56 | $654 |
| Duloxetine Hcl | 14 | $614 |
| Gabapentin | 23 | $562 |
| Rosuvastatin Calcium | 47 | $535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $263 | $66,09960 claims |
| Boehringer IngelheimJardiance | $101 | $38,52132 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $408 | $32,49334 claims |
| PfizerEliquis | $193 | $18,99219 claims |
| GSKAnoro Ellipta | $87 | $5,40712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Carbondale
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.